Market Research Logo

Myotonic Dystrophy - Pipeline Review, H1 2015

Myotonic Dystrophy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Myotonic Dystrophy - Pipeline Review, H1 2015’, provides an overview of the Myotonic Dystrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myotonic Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myotonic Dystrophy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myotonic Dystrophy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Myotonic Dystrophy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Myotonic Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Myotonic Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Myotonic Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Myotonic Dystrophy Overview
Therapeutics Development
Pipeline Products for Myotonic Dystrophy - Overview
Pipeline Products for Myotonic Dystrophy - Comparative Analysis
Myotonic Dystrophy - Therapeutics under Development by Companies
Myotonic Dystrophy - Therapeutics under Investigation by Universities/Institutes
Myotonic Dystrophy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Myotonic Dystrophy - Products under Development by Companies
Myotonic Dystrophy - Products under Investigation by Universities/Institutes
Myotonic Dystrophy - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Isis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Prosensa Therapeutics B.V.
Sarepta Therapeutics, Inc.
Valentia Biopharma S.L.
Myotonic Dystrophy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense Oligonucleotide for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-DMPKRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRO-135 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Oligonucleotide for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-149 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-152 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-0411 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLT-025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myotonic Dystrophy - Recent Pipeline Updates
Myotonic Dystrophy - Product Development Milestones
Featured News & Press Releases
Feb 25, 2014: VLT Biopharma gets the Orphan Drug designation for VLT015
Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy
Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myotonic Dystrophy, H1 2015
Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Myotonic Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Myotonic Dystrophy - Pipeline by Genzyme Corporation, H1 2015
Myotonic Dystrophy - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Myotonic Dystrophy - Pipeline by Marina Biotech, Inc., H1 2015
Myotonic Dystrophy - Pipeline by Prosensa Therapeutics B.V., H1 2015
Myotonic Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H1 2015
Myotonic Dystrophy - Pipeline by Valentia Biopharma S.L., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Myotonic Dystrophy Therapeutics - Recent Pipeline Updates, H1 2015
List of Figures
Number of Products under Development for Myotonic Dystrophy, H1 2015
Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report